CN105535037A - Application of chimonanthus nitens leave tablet in preparing drug for inhibiting embryonic carcinoma cell P19 cell proliferation - Google Patents

Application of chimonanthus nitens leave tablet in preparing drug for inhibiting embryonic carcinoma cell P19 cell proliferation Download PDF

Info

Publication number
CN105535037A
CN105535037A CN201510984149.2A CN201510984149A CN105535037A CN 105535037 A CN105535037 A CN 105535037A CN 201510984149 A CN201510984149 A CN 201510984149A CN 105535037 A CN105535037 A CN 105535037A
Authority
CN
China
Prior art keywords
blade
cell
chimonanthus nitens
preparation
chimonanthusn itens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201510984149.2A
Other languages
Chinese (zh)
Inventor
李晶
杨志华
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jinan Xinshidai Medicine Science and Technology Co Ltd
Original Assignee
Jinan Xinshidai Medicine Science and Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jinan Xinshidai Medicine Science and Technology Co Ltd filed Critical Jinan Xinshidai Medicine Science and Technology Co Ltd
Priority to CN201510984149.2A priority Critical patent/CN105535037A/en
Publication of CN105535037A publication Critical patent/CN105535037A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention belongs to the technical field of traditional Chinese medicine, and in particular relates to application of a chimonanthus nitens leave tablet in preparing a drug for inhibiting embryonic carcinoma cell P19 cell proliferation, and a preparation method of the chimonanthus nitens leave tablet. The chimonanthus nitens leave tablet is prepared by taking 1500g of chimonanthus nitens leaves as a crude drug and adopting supercritical extraction, and the content of quercetin and kaempferol is greatly improved.

Description

Chimonanthusn itens Oliv. blade suppresses the application in teratocarcinoma cell P19 cell proliferation in preparation
Technical field
The invention belongs to technical field of Chinese medicines, be specifically related to the application of a kind of Chimonanthusn itens Oliv. blade in preparation suppression teratocarcinoma cell P19 cell proliferation and the preparation method of Chimonanthusn itens Oliv. blade.
Background technology
Chimonanthusn itens Oliv. blade standard No. WS-11310 (ZD-1310)-2002, is recorded in national standard for traditional Chinese medicines compilation internal medicine internal medicine lung system (one) fascicle.Be made up as crude drug of leaf of Chimonanthus Nitens 1500g, there are relieving the exterior syndrome with drugs of pungent in flavor and cool in nature, effect of heat-clearing and toxic substances removing.For anemopyretic cold, heating, aversion to cold, pharyngalgia.
In prior art, not yet there is Chimonanthusn itens Oliv. blade at the report suppressing the application in mouse teratocarcinoma cells P19 cell proliferation in preparation, also extract there are no Chimonanthusn itens Oliv. blade the report that preparation aspect adopts supercritical extraction, and the method for soak by water, extraction by steam distillation volatile oil, technique is coarse, backward, and impurity is many, causes patient's consumption excessive, be inconvenient to take, had a strong impact on this product and applied clinically.
Summary of the invention
Goal of the invention: the object of the present invention is to provide a kind of Chimonanthusn itens Oliv. blade to suppress the application in teratocarcinoma cell P19 cell proliferation in preparation.
Another object of the present invention is the preparation method providing a kind of Chimonanthusn itens Oliv. blade.
The object of the invention is by following scheme realize:
Chimonanthusn itens Oliv. blade suppresses the application in teratocarcinoma cell P19 cell proliferation in preparation, and described Chimonanthusn itens Oliv. blade is made up as crude drug of leaf of Chimonanthus Nitens 1500g, and the preparation method of described Chimonanthusn itens Oliv. blade is made up of the following step: get leaf of Chimonanthus Nitens, join CO 2in supercritical extraction device, ethanol is as entrainer, and the percent by volume that entrainer accounts for total extractant is 4-6%, extracting pressure 15-30MPa, temperature 30-50 DEG C, CO 2flow l-3ml/g crude drug min, extraction time 700-800min, obtains supercritical extract, and supercritical extract is added starch, 70% ethanol granule, and dry, tabletting, makes 500, the heavy 0.35g of every sheet.
Preferably, above-mentioned Chimonanthusn itens Oliv. blade suppresses the application in teratocarcinoma cell P19 cell proliferation in preparation, and the preparation method of described Chimonanthusn itens Oliv. blade is made up of the following step: get leaf of Chimonanthus Nitens, join CO 2in supercritical extraction device, ethanol is as entrainer, and the percent by volume that entrainer accounts for total extractant is 5%, extracting pressure 25MPa, temperature 40 DEG C, CO 2flow 2ml/g crude drug min, extraction time 750min, obtains supercritical extract, and supercritical extract is added starch, 70% ethanol granule, and dry, tabletting, makes 500, the heavy 0.35g of every sheet.
In prior art, Chimonanthusn itens Oliv. blade is oral, one time 6 ~ 7,3 times on the one.Chimonanthusn itens Oliv. blade dosage is large.The heavy 0.35g of the every sheet of the Chimonanthusn itens Oliv. blade adopting the inventive method to be prepared into, only needs 3 at every turn, within 1st, takes 3 times.Dose is greatly reduced under the condition with more active component.This conclusion can be proved by following test.
The comparison of Quercetin and kaempferol content in Chimonanthusn itens Oliv. blade prepared by test one, distinct methods
L, instrument and reagent Chimonanthusn itens Oliv. blade of the present invention: by the preparation of embodiment 1 method, use 1500g crude drug, makes 500 through extracting, the heavy 0.35g of every sheet.Former Chimonanthusn itens Oliv. blade, prepares according to WS-11310 (ZD-1310)-2002 standard method.Agilent1200 high performance liquid chromatograph; METTLERAE240 electronic analytical balance; Quercetin and kaempferol reference substance (Nat'l Pharmaceutical & Biological Products Control Institute).
2, method
Measure according to high performance liquid chromatography (Chinese Pharmacopoeia version in 2010 annex VI D).
Chromatographic condition and system suitability octadecylsilane chemically bonded silica are filler; Methanol-0.5% phosphoric acid solution (45: 55) is mobile phase; Determined wavelength is 365nm.Number of theoretical plate calculates all should be not less than 1500 by Quercetin, kaempferol peak respectively.
The preparation precision of reference substance solution takes Quercetin, kaempferol reference substance is appropriate, adds methanol respectively and makes the solution of every 1ml containing 6 μ g, 8 μ g, to obtain final product.
10, Chimonanthusn itens Oliv. blade of the present invention is got in the preparation of need testing solution, accurately weighed, porphyrize, get 0.60g, accurately weighed, add methanol reflux 2 times (50ml, 50ml), each 1 hour, filter, merging filtrate, residue adds methanol and washs in right amount, and filter, washing liquid is incorporated in filtrate, evaporate to dryness, the residue 30ml that adds water makes dissolving, with glacial acetic acid adjust ph to 3 ~ 4, adds ethyl acetate jolting and extracts 5 times, each 30ml, merge ethyl acetate liquid, evaporate to dryness, residue adds methanol makes dissolving in right amount, be transferred in 10ml measuring bottle, add methanol to scale, shake up, to obtain final product.
20, the Chimonanthusn itens Oliv. blade of contrast is got in the preparation of reference product need testing solution, accurately weighed, porphyrize, get 1.2g, accurately weighed, add methanol reflux 2 (50ml, 50ml), each 1 hour, filter, merging filtrate, residue adds methanol and washs in right amount, filter, washing liquid is incorporated in filtrate, evaporate to dryness, the residue 30ml that adds water makes dissolving, with glacial acetic acid adjust ph to 3 ~ 4, add ethyl acetate jolting and extract 5 times, each 30ml, merge ethyl acetate liquid, evaporate to dryness, residue adds methanol makes dissolving in right amount, be transferred in 10ml measuring bottle, add methanol to scale, shake up, obtain.
Algoscopy is accurate respectively draws reference substance solution and need testing solution, each 5 μ l of reference product need testing solution, injection liquid chromatography, measures, to obtain final product.
3, result
Result shows, in Chimonanthusn itens Oliv. blade of the present invention, the content of Quercetin and kaempferol is 220-362 μ g/ sheet; And the content of Quercetin and kaempferol is 36 μ g/ grains in former Chimonanthusn itens Oliv. blade, each serving the Quercetin of consumption 3 and kaempferol content be the 3-5 of former tablet 6 content doubly, when dose reduces, Quercetin and kaempferol content improve a lot.
Above-mentioned research shows, adopts Chimonanthusn itens Oliv. blade prepared by preparation method of the present invention, Chimonanthusn itens Oliv. blade prepared by the method that active constituent content is recorded higher than WS-11310 (ZD-1310)-2002 standard far away.
Detailed description of the invention
Below in conjunction with specific embodiment, the present invention is further described, so that those skilled in the art more understands the present invention, but this should be interpreted as that the scope of the above-mentioned theme of the present invention is only limitted to following example, all technology realized based on foregoing of the present invention all belong to scope of the present invention.
Embodiment 1
Get leaf of Chimonanthus Nitens 1500g, join CO 2in supercritical extraction device, ethanol is as entrainer, and the percent by volume that entrainer accounts for total extractant is 5%, extracting pressure 25MPa, temperature 40 DEG C, CO 2flow 2ml/g crude drug min, extraction time 750min, obtains supercritical extract, and supercritical extract is added starch, 70% ethanol granule, and dry, tabletting, makes 500, the heavy 0.35g of every sheet.
After testing, in finished product, the content of Quercetin and kaempferol is 362 μ g/ sheets.
Embodiment 2
Get leaf of Chimonanthus Nitens 1500g, join CO 2in supercritical extraction device, ethanol is as entrainer, and the percent by volume that entrainer accounts for total extractant is 4%, extracting pressure 15MPa, temperature 30 DEG C, CO 2flow 1ml/g crude drug min, extraction time 800min, obtains supercritical extract, and supercritical extract is added starch, 70% ethanol granule, and dry, tabletting, makes 500, the heavy 0.35g of every sheet.
After testing, in finished product, the content of Quercetin and kaempferol is 220 μ g/ sheets.
Embodiment 3
Get leaf of Chimonanthus Nitens 1500g, join CO 2in supercritical extraction device, ethanol is as entrainer, and the percent by volume that entrainer accounts for total extractant is 6%, extracting pressure 30MPa, temperature 60 C, CO 2flow 3ml/g crude drug min, extraction time 700min, obtains supercritical extract, and supercritical extract is added starch, 70% ethanol granule, and dry, tabletting, makes 500, the heavy 0.35g of every sheet.
After testing, in finished product, the content of Quercetin and kaempferol is 308 μ g/ sheets.
Embodiment 4: Chimonanthusn itens Oliv. blade suppresses the experimentation data of teratocarcinoma cell P19 cell proliferation
1. experiment material
1.1 experiment cell strains
Mouse teratocarcinoma cells P19 cell, Shandong University's laboratory cell storehouse, DMEM+10%FBS cellar culture.
1.2 Experimental agents
Drugs: Chimonanthusn itens Oliv. blade of the present invention: prepare by embodiment 1 method.
Medicinal liquid liquid storage: take 100mg Chimonanthusn itens Oliv. blade, is dissolved in 5ml dehydrated alcohol, 0.2 μm of frit, 500 μ ldoff pipe subpackages ,-20 DEG C of storages, and simultaneously 0.2 μm of frit dehydrated alcohol is in order to the use of matched group.
1.3 experiment reagent
DMEM (GIBCO company Cat.No.12100-061Lot.No.758137); Hyclone (Tian Hang bio tech ltd, Zhejiang Lot.No.100419); NaHC0 3(Shanghai hundred million chemical reagent company limited Cat.No.11810-033Lot.No.1088387 of a specified duration); Trypsin(AMRESCO company); EDTA(AMRESCO company); PenicillinGSodiumSalt(AMRESCO company 1); StreptomycinSulfate (AMRESCO); Dehydrated alcohol (Zibo Ya Dulan Trade Co., Ltd.); MTT (Biosharp lot number: 0793): PBS(laboratory autogamy);
1.4 experiment equipment
Lycra inverted microscope (German Leica model: DMIL); Visible-ultraviolet light microwell plate detector (MD company of U.S. model: SPECTRAMAX190); C0 2incubator (FORMA model: 3111); Super-clean bench (safe and sound Inc. of Su Jing group moulding number: SW-CJ-ZFD); Pure water instrument (Sprlng company of U.S. model: S/N020579); Accurate pipettor (French Gilson Inc model: P2); Electronic balance (German Sai Duolisi company limited model: BT323S); Full-automatic high-pressure autoclave (Japanese SANYO company model: MLS-3020); Table electrothermal air dry oven (the accurate experimental facilities company in Shanghai model: DHG9123A); Refrigerator (Siemens Company's model: KG18V21TI); Liquid nitrogen container (CBS model: 2001); Low speed centrifuge (Anting Scientific Instrument Factory, Shanghai's model: KA-1000); 0.2 μm of filter (MILLIPORE model: SLGP033RB); 1cm culture dish (NEST company), 96 well culture plates (NEST company); Cell counting count board; Centrifuge tube, pipet, Tips are some.
2. experimental technique
1) P19 cell DMEM+10%FBS is in 37 DEG C, 5%C0 2carry out cellar culture (10cm culture dish), when Growth of Cells is to logarithmic (log) phase, collecting cell, discards culture fluid, PBS fine laundering 3 times, add 3ml0.25% trypsin-0.04%EDTA, after 37 DEG C of digestion 2min, add 5ml complete medium neutralization reaction wherein, proceeded in centrifuge tube after piping and druming cell, the centrifugal 5min of 1000rpm, adjustment concentration of cell suspension 3 × 10 4individual/ml.
2) enter in 96 well culture plates by cell kind, every hole adds cell suspension 180 μ l, culture plate put into cell culture incubator (37 DEG C, 5%C0 2) cellar culture.
3) according to cell growth status, generally grow to 50%-70%, add Chimonanthusn itens Oliv. blade solution, continue to cultivate 24h.
4) add 20 μ lMTT solution (5mg/ml, i.e. 0.5%MTT) after 24h, continue to cultivate 4h.
5) after 4h, buckle method removes supernatant, pats dry gently with absorbent paper, and every hole adds 200 μ l dimethyl sulfoxide, puts low-speed oscillation 10min on shaking table, crystal is fully dissolved.The light absorption value in each hole is measured at enzyme-linked immunosorbent assay instrument 490nm place.
6) background (do not add cell, only add culture fluid) is set, control wells (the medicine dissolution medium of cell, same concentrations, culture fluid, MTT, dimethyl sulfoxide) simultaneously, often organizes the multiple hole of setting 6.
7) result represents with the suppression ratio of medicine to cell: cell proliferation suppression ratio (%)=(control wells OD value-dosing holes OD value), control wells OD value × 100%.Experiment repetition 3 times.
3. statistical disposition
Adopt the correlation analysis in MicrosoftExcel2007 software and Studentt inspection, data represent with mean ± S.D..
4. experimental result
Statistical result showed after mtt assay experiment, compare with matched group, when dosage reaches 5mg/ml, to P19 cell inhibitory effect variant (P<0.05), dosage this difference when 10mg/ml has significance (P<0.01), has pole significant difference (P<0.001) when dosage reaches 15-20mg/ml.
Table 1 Chimonanthusn itens Oliv. blade is to P19 cell inhibitory effect influence research (X ± SD)
Group Drug level (mg/ml) Suppression ratio (%)
Matched group 0 0
1 5 7.94±4.18
2 10 15.63±6.42*
3 15 25.99±9.46**
4 20 35.13±11.79**
Note: compare with matched group, * P<O.01; * P<0.001.
5. experiment conclusion
Chimonanthusn itens Oliv. blade of the present invention can suppress P19 cell proliferation, and reduce the Growth of Cells number of P19 cell, this effect is dose dependent.

Claims (2)

1. Chimonanthusn itens Oliv. blade suppresses the application in teratocarcinoma cell P19 cell proliferation in preparation, described Chimonanthusn itens Oliv. blade is made up as crude drug of leaf of Chimonanthus Nitens 1500g, it is characterized in that, the preparation method of described Chimonanthusn itens Oliv. blade is made up of the following step: get leaf of Chimonanthus Nitens, join CO 2in supercritical extraction device, ethanol is as entrainer, and the percent by volume that entrainer accounts for total extractant is 4-6%, extracting pressure 15-30MPa, temperature 30-50 DEG C, CO 2flow l-3ml/g crude drug min, extraction time 700-800min, obtains supercritical extract, and supercritical extract is added starch, 70% ethanol granule, and dry, tabletting, makes 500, the heavy 0.35g of every sheet.
2. the Chimonanthusn itens Oliv. blade according to claim l suppresses the application in teratocarcinoma cell P19 cell proliferation in preparation, and it is characterized in that, the preparation method of described Chimonanthusn itens Oliv. blade is made up of the following step: get leaf of Chimonanthus Nitens, join CO 2in supercritical extraction device, ethanol is as entrainer, and the percent by volume that entrainer accounts for total extractant is 5%, extracting pressure 25MPa, temperature 40 DEG C, CO 2flow 2ml/g crude drug min, extraction time 750min, obtains supercritical extract, and supercritical extract is added starch, 70% ethanol granule, and dry, tabletting, makes 500, the heavy 0.35g of every sheet.
CN201510984149.2A 2015-12-24 2015-12-24 Application of chimonanthus nitens leave tablet in preparing drug for inhibiting embryonic carcinoma cell P19 cell proliferation Withdrawn CN105535037A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510984149.2A CN105535037A (en) 2015-12-24 2015-12-24 Application of chimonanthus nitens leave tablet in preparing drug for inhibiting embryonic carcinoma cell P19 cell proliferation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510984149.2A CN105535037A (en) 2015-12-24 2015-12-24 Application of chimonanthus nitens leave tablet in preparing drug for inhibiting embryonic carcinoma cell P19 cell proliferation

Publications (1)

Publication Number Publication Date
CN105535037A true CN105535037A (en) 2016-05-04

Family

ID=55814962

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510984149.2A Withdrawn CN105535037A (en) 2015-12-24 2015-12-24 Application of chimonanthus nitens leave tablet in preparing drug for inhibiting embryonic carcinoma cell P19 cell proliferation

Country Status (1)

Country Link
CN (1) CN105535037A (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103494878A (en) * 2013-10-08 2014-01-08 南京正亮医药科技有限公司 Preparation method and application of compound danshen tablets

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103494878A (en) * 2013-10-08 2014-01-08 南京正亮医药科技有限公司 Preparation method and application of compound danshen tablets

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
国家药品监督管理局: "《国家中成药标准汇编内科肺系（一）分册》", 1 December 2002 *
李莎莎等: ""山蜡梅化学成分及药理作用的研究进展"", 《华西药学杂志》 *

Similar Documents

Publication Publication Date Title
CN105535515A (en) Application of Lvji cough asthma tablets to preparation of medicine for inhibiting cell proliferation of prostate cancer cells PC-3
CN105412170A (en) Application of chimonanthus nitens leaf tablets in preparing medicine for inhibiting cell proliferation of breast tumor cell C127
CN103735785B (en) Pure and impure of ferrum broom suppresses the application in lymphoma cell YAC-1 cell proliferation in preparation
CN105535037A (en) Application of chimonanthus nitens leave tablet in preparing drug for inhibiting embryonic carcinoma cell P19 cell proliferation
CN105380971A (en) Application of chimonanthus nitens leaf tablets to preparing medicine for suppressing proliferation of lymphoma EL4 cells
CN105412176A (en) Application of chimonanthus nitens leaf tablets in preparing medicine for inhibiting cell proliferation of laryngocarcinoma cell Hep-2
CN105395580A (en) Application of folium chimonanthi nitentis tablet to preparation of drug for inhibiting human colonadenocarcinoma cell line (HCT-8) cell proliferation
CN105412174A (en) Application of chimonanthus nitens leaf tablets in preparing medicine for inhibiting cell proliferation of ovarian carcinoma cell A2780
CN105412172A (en) Application of chimonanthus nitens leaf tablets in preparing medicine for inhibiting cell proliferation of rat hypophysoma cell MMQ
CN105456313A (en) Application of chimonanthus nitens oliv.leaves in preparation of medicine for inhibiting pheochromocytoma cell PC-12 cell proliferation
CN105477031A (en) Application of chimonanthus nitens oliv.leaves in preparation of medicine for inhibiting lymphoma cell U-937 cell proliferation
CN105412171A (en) Application of chimonanthus nitens leaf tablets in preparing medicine for inhibiting cell proliferation of rhabdomyosarcoma cell A-204
CN105434487A (en) Application of chimonanthus nitens leaf tablets in preparing medicine for inhibiting cell proliferation of melanoma cell B16
CN105535038A (en) Application of chimonanthus nitens tablet in preparing drug for inhibiting esophagus cancer cell EC109 cell proliferation
CN105412173A (en) Application of chimonanthus nitens leaf tablets in preparing medicine for inhibiting cell proliferation of gastric adenocarcinoma cell BGC-823
CN105434489A (en) Application of chimonanthus nitens leaf tablets in preparing medicine for inhibiting cell proliferation of skin basal cell carcinoma cell A431
CN105380969A (en) Application of chimonanthus nitens leaf tablets to preparing medicine for suppressing proliferation of HeLa cells
CN105412175A (en) Application of chimonanthus nitens leaf tablets in preparing medicine for inhibiting cell proliferation of uterus well-differentiated squamous cancer cell HCC
CN105362317A (en) Application of chimonanthus nitens leaf blades in preparing drug for inhibiting JAR cell proliferation of placental villus cancer cells
CN105380970A (en) Application of chimonanthus nitens leaf tablets to preparing medicine for suppressing proliferation of malignant embryonal rhabdomyoma (RD) cells
CN105434488A (en) Application of chimonanthus nitens leaf tablets in preparing medicine for inhibiting cell proliferation of cranial nerve tumor cell Neuro-2a
CN105412333A (en) Application of hance brandisia herb tablets in preparation of medicine for inhibiting cell proliferation of glioma cells SHG-44
CN105395581A (en) Application of folium chimonanthi nitentis tablet to preparation of drug for inhibiting skin melanophore A375 cell proliferation
CN105343292A (en) Application of hance brandisia herb tablets in preparation of drugs for inhibiting endometrial carcinoma cell HEC-1B proliferation
CN105816536A (en) Application of lawn pennywort herb liver-healing tablets in preparation of drug for inhibiting cell proliferation of cerebral tumor cells SF767

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication

Application publication date: 20160504

WW01 Invention patent application withdrawn after publication